:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/DOQKYOWAGFGZ3CWZT7BHX3MIZA.jpg)
Pfizer Inc. and its German partner BioNTech SE have applied to the U.S. Food and Drug Administration for emergency use authorization of their COVID-19 vaccine booster for children aged 6 months through 4 years.
The bivalent vaccine targets the original strain of the COVID-19 virus, plus the BA.4 and BA.5 omicron subvariants.
An authorization from the FDA would mean that children would receive the primary vaccine series — two doses of the original Pfizer-BioNTech COVID-19 vaccine — and then one shot of the omicron-adapted bivalent vaccine.
The omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine was authorized as a booster dose for ages 5 years and older in the U.S. in October.
©2022 Cox Media Group
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/LLENQYITEREXVFPITOFJ2IGEH4.jpg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/6N5UZVEUKZHHTPVRGF7ZDL7ECI.jpg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/7V46ACI2ZBHGVNDS3SW5PREW74.png)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/TCUCJVMDNJBZVK32IO7UGLWYQY.jpeg)
:quality(70)/cloudfront-us-east-1.images.arcpublishing.com/cmg/B62QQBSTIFBZJOQD2O7LFC3UCY.png)